The Vanguard Group 13D and 13G filings for Intellia Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-08 11:29 am Purchase | 2024-12-31 | 13G | Intellia Therapeutics, Inc. NTLA | The Vanguard Group | 10,189,953 10.000% | 1,842,504 (+22.07%) | Filing |
| 2024-02-13 5:07 pm Purchase | 2023-12-29 | 13G | Intellia Therapeutics, Inc. NTLA | The Vanguard Group | 8,347,449 9.320% | 537,223 (+6.88%) | Filing |
| 2023-02-09 11:22 am Purchase | 2022-12-30 | 13G | Intellia Therapeutics, Inc. NTLA | The Vanguard Group | 7,810,226 9.280% | 1,367,871 (+21.23%) | Filing |
| 2022-02-10 08:17 am Purchase | 2021-12-31 | 13G | Intellia Therapeutics, Inc. NTLA | The Vanguard Group | 6,442,355 8.660% | 1,311,158 (+25.55%) | Filing |
| 2021-02-10 11:03 am Purchase | 2020-12-31 | 13G | Intellia Therapeutics, Inc. NTLA | The Vanguard Group | 5,131,197 7.980% | 1,606,998 (+45.60%) | Filing |